Is RXRX or SABS more undervalued in 2026?

CirclFi compares Recursion Pharmaceuticals, Inc. (RXRX) and SAB Biotherapeutics, Inc. (SABS) using 13 institutional-grade valuation models. RXRX has a Quality of Company score of 6.5/10 while SABS scores 5.0/10.

Which is a better buy — RXRX or SABS?

Compare intrinsic values from 13 independent models against current market prices. CirclFi also calculates Value Trap scores. This is not financial advice — conduct your own analysis.

How do RXRX and SABS valuations compare?

RXRX at $3.59 and SABS at $3.60 are compared across Bayesian DCF, EPV, EROIC Spread, First Chicago, Markov DDM, and 8 additional models.

RXRX vs SABS Valuation Comparison 2026 — Intrinsic Value Analysis

RXRX

Biological Products, (No Diagnostic Substances)

Recursion Pharmaceuticals, Inc.

Quality

6.5

out of 10

Value Trap

LOW

Price

$3.59

Last close

Models

9/13

Active

SABS

Biological Products, (No Diagnostic Substances)

SAB Biotherapeutics, Inc.

Quality

5.0

out of 10

Value Trap

WARN

Price

$3.60

Last close

Models

12/13

Active

Model-by-Model Comparison

Model	Type	RXRX Fair Value	RXRX Upside	SABS Fair Value	SABS Upside
Bayesian DCF	Intrinsic	$1.39	-61.2%	$1.27	-64.8%
Earnings Power Value	Intrinsic	—	—	$6.17	+77.9%
EROIC Spread	Intrinsic	$•••.••	••.•%	$•••.••	••.•%
First Chicago	Scenario	$•••.••	••.•%	$•••.••	••.•%
ML-RIV	Intrinsic	$•••.••	••.•%	$•••.••	••.•%
Dynamic NAV	Asset-Based	$1.99	-44.6%	$1.90	-47.2%
PWERM	Option-Based	$•••.••	••.•%	$•••.••	••.•%
Regime Cross-Sectional	Relative	$•••.••	••.•%	$•••.••	••.•%
Sentiment SOTP	Hybrid	$•••.••	••.•%	$•••.••	••.•%
CUCE Ensemble	Ensemble	$•••.••	••.•%	$•••.••	••.•%
FTNN Topology	Relative	$•••.••	••.•%	$•••.••	••.•%
RCMH-DCF	Intrinsic	$•••.••	••.•%	$•••.••	••.•%

🔒

Unlock Full 13-Model Comparison

Access all valuation models for RXRX vs SABS — including EROIC Spread, First Chicago, Markov DDM, PWERM, and 7 more.

Access Full Analysis — From $27/mo →

RXRX vs SABS — Which Stock Is More Undervalued?

RXRX scores higher with a 6.5/10 quality rating vs SABS's 5.0/10. Both stocks are analyzed daily using SEC EDGAR filings across 13 independent models.

Comparing Recursion Pharmaceuticals, Inc. (RXRX) and SAB Biotherapeutics, Inc. (SABS) across 13 institutional-grade valuation models reveals how each company's intrinsic value stacks up against its market price. CirclFi's engine processes SEC EDGAR 10-K and 10-Q filings, FRED macroeconomic data, and GDELT news sentiment to generate independent fair value estimates daily.

RXRX currently trades at $3.59 with a QOC of 6.5/10, while SABS trades at $3.60 with a QOC of 5.0/10.

Both companies are analyzed with models spanning intrinsic (Bayesian DCF, EPV), scenario-based (First Chicago), regime-switching (Markov DDM, RCMH-DCF), machine learning (ML-RIV, FTNN Topology), and ensemble methods (CUCE).